Grant Thornton's strategic addition of Krystn Hammond as a CFO Advisory principal underscores the firm's commitment to strengthening its advisory capabilities within the life sciences sector. Hammond's extensive background, spanning transactions and tax restructurings for high-profile pharmaceutical and biotech clients, aligns seamlessly with Grant Thornton's mission to provide industry-specific, value-driven solutions. Her role will undoubtedly enhance the firm's ability to deliver comprehensive valuation services, helping clients navigate the complexities of the ever-evolving life sciences landscape. This move reflects Grant Thornton’s proactive approach to meeting the unique needs of its clients with specialized expertise and strategic insight.